A Study of ZL-1211 in Patients With Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
This study is a Phase I/II, open-label, dose escalation, and cohort expansion study designed
to characterize the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD),
immunogenicity, and preliminary antitumor activity of ZL-1211 administered by IV infusion on
a every 2 weeks (Q2W) schedule.